written on 23.05.2014
Tags:
,

Roche gets thumbs up for CLL use of Gazyvaro in EU

TAGS: ,

Gazyva, Roche's successor to Rituxan, is already approved in the U.S. for first-line use on chronic lymphocytic leukemia (CLL) and appears poised for the same in Europe. The EU Committee for Medicinal Products for Human Use (CHMP) today recommended it for approval there.

Latest Report